Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 12,377 shares, an increase of 92.5% from the October 15th total of 6,429 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily trading volume, of 37,998 shares, the short-interest ratio is currently 0.3 days.
Neuphoria Therapeutics Stock Down 2.7%
NEUP opened at $2.48 on Tuesday. Neuphoria Therapeutics has a 52-week low of $2.45 and a 52-week high of $5.53. The company has a 50 day moving average of $3.34 and a two-hundred day moving average of $4.08. The company has a market cap of $13.42 million, a P/E ratio of -0.40 and a beta of 0.77.
Analyst Upgrades and Downgrades
NEUP has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, August 27th. Wall Street Zen raised Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 25th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $7.00.
View Our Latest Stock Report on Neuphoria Therapeutics
Institutional Trading of Neuphoria Therapeutics
A hedge fund recently bought a new stake in Neuphoria Therapeutics stock. ADAR1 Capital Management LLC bought a new stake in Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 30,000 shares of the company’s stock, valued at approximately $131,000. ADAR1 Capital Management LLC owned approximately 0.56% of Neuphoria Therapeutics as of its most recent filing with the Securities & Exchange Commission. 15.90% of the stock is owned by hedge funds and other institutional investors.
Neuphoria Therapeutics Company Profile
Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.
Further Reading
- Five stocks we like better than Neuphoria Therapeutics
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
